Travis Steed, an analyst from Bank of America Securities, maintained the Buy rating on Intuitive Surgical. The associated price target remains the same with $650.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Travis Steed has given his Buy rating due to a combination of factors that highlight Intuitive Surgical’s innovative approach and growth potential. The company is actively involved in pioneering research with the JURA Imaging System, which is expected to enhance surgical outcomes by improving imaging capabilities. This aligns with Intuitive Surgical’s commitment to innovation and improving the standard of care, thereby reducing variability in surgical procedures and achieving better patient outcomes.
Additionally, the advancements in deep learning and imaging technologies, such as Single Snapshot Imaging of Optical Properties (SSOP), are poised to provide more accurate and quantitative imaging during surgeries. These technological improvements are expected to replace or augment current imaging agents, leading to more predictable and efficient surgical workflows. The promising pipeline and robust growth outlook further support the Buy rating, as these developments are likely to sustain the company’s market leadership and drive future growth.
According to TipRanks, Steed is a 4-star analyst with an average return of 7.0% and a 60.00% success rate. Steed covers the Healthcare sector, focusing on stocks such as Intuitive Surgical, Boston Scientific, and Medtronic.
In another report released on November 19, Bernstein also assigned a Buy rating to the stock with a $700.00 price target.